Newsfeeds - Spark Newswire

1 minute read

Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial

Today, 12:26 PM

Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell carcinoma that is resistant to prior immunotherapy.

BMY

4 minute read

Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 12:26 PM

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…

BCYC

7 minute read

Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday

By Lisa Levin

Today, 12:26 PM

Gainers Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB) shares jumped 187.3% to close at $48.03 on Monday after gaining around 18% on Friday.

AEMD

2 minute read

Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights

Today, 12:26 PM

AEMD

5 minute read

This Biotechnology Stock Is Trading Lower By 77%, Here Are 62 Stocks Moving In Monday’s Mid-Day Session

By Lisa Levin

Today, 12:26 PM

Gainers Ontrak, Inc. (NASDAQ: OTRK) gained 102% to $1.3150. Ontrak is expected to report financial results for the second quarter on Tuesday, August 9, 2022.

AEMD

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 12:26 PM

Gainers Nanobiotix (NASDAQ:NBTX) shares rose 16.4% to $2.7 during Friday's after-market session. The company's market cap stands at $94.1 million.

AVRO

18 minute read

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 12:26 PM

During Wednesday's session, 326 stocks hit new 52-week lows.

AAOI

12 minute read

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

Today, 12:26 PM

On Friday, 319 stocks hit new 52-week lows.

ADI

8 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 12:26 PM

On Thursday, 126 companies set new 52-week lows.

AHI

5 minute read

Events
News

NANOBIOTIX Announced New Data Presented at ASCO Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications

By Charles Gross

Today, 12:26 PM

NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination wit

NBTX